Is Janux Therapeutics Stock a Good Investment?
Janux Therapeutics Investment Advice | JANX |
- Examine Janux Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Janux Therapeutics' leadership team and their track record. Good management can help Janux Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Janux Therapeutics' business and its evolving consumer preferences.
- Compare Janux Therapeutics' performance and market position to its competitors. Analyze how Janux Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Janux Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Janux Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Janux Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Janux Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Janux Therapeutics Stock
Researching Janux Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 93.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Janux Therapeutics recorded a loss per share of 1.28. The entity had not issued any dividends in recent years.
To determine if Janux Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Janux Therapeutics' research are outlined below:
| Janux Therapeutics generated a negative expected return over the last 90 days | |
| Janux Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 10.59 M. Net Loss for the year was (68.99 M) with loss before overhead, payroll, taxes, and interest of (57.8 M). | |
| Janux Therapeutics currently holds about 338.76 M in cash with (43.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.15. | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Diraimondo Thomas of 84000 shares of Janux Therapeutics at 53.24 subject to Rule 16b-3 |
Janux Therapeutics Quarterly Gross Profit |
|
Janux Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Janux Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Janux Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Janux Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Janux Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-09 | 2022-06-30 | -0.37 | -0.41 | -0.04 | 10 | ||
2022-05-10 | 2022-03-31 | -0.37 | -0.32 | 0.05 | 13 | ||
2023-05-09 | 2023-03-31 | -0.49 | -0.42 | 0.07 | 14 | ||
2021-11-09 | 2021-09-30 | -0.18 | -0.26 | -0.08 | 44 | ||
2022-11-10 | 2022-09-30 | -0.49 | -0.4 | 0.09 | 18 | ||
2025-02-28 | 2024-12-31 | -0.4533 | -0.36 | 0.0933 | 20 | ||
2023-08-08 | 2023-06-30 | -0.52 | -0.42 | 0.1 | 19 | ||
2023-03-10 | 2022-12-31 | -0.49 | -0.39 | 0.1 | 20 |
Janux Therapeutics Target Price Consensus
Janux target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Janux Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 14 | Strong Buy |
Most Janux analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Janux stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Janux Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationJanux Therapeutics Target Price Projection
Janux Therapeutics' current and average target prices are 29.94 and 90.23, respectively. The current price of Janux Therapeutics is the price at which Janux Therapeutics is currently trading. On the other hand, Janux Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Janux Therapeutics Market Quote on 24th of March 2025
Target Price
Analyst Consensus On Janux Therapeutics Target Price
Janux Therapeutics Analyst Ratings
Janux Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Janux Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Janux Therapeutics' financials, market performance, and future outlook by experienced professionals. Janux Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Janux Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Janux Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Janux Therapeutics backward and forwards among themselves. Janux Therapeutics' institutional investor refers to the entity that pools money to purchase Janux Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 1.3 M | Lord, Abbett & Co Llc | 2024-12-31 | 1.3 M | Logos Global Management Lp | 2024-12-31 | 1.2 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.1 M | Holocene Advisors, Lp | 2024-12-31 | 1 M | Perceptive Advisors Llc | 2024-12-31 | 817.9 K | Bank Of America Corp | 2024-12-31 | 794.8 K | Orbimed Advisors, Llc | 2024-12-31 | 758.6 K | Avidity Partners Management Lp | 2024-12-31 | 741.9 K | Ra Capital Management, Llc | 2024-12-31 | 10.4 M | Fmr Inc | 2024-12-31 | 8.7 M |
Janux Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.77 B.Market Cap |
|
Janux Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.06) | (0.07) | |
| Return On Capital Employed | (0.09) | (0.09) | |
| Return On Assets | (0.06) | (0.07) | |
| Return On Equity | (0.07) | (0.06) |
Determining Janux Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Janux Therapeutics is a good buy. For example, gross profit margin measures Janux Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Janux Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Janux Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Janux Therapeutics. Check Janux Therapeutics' Beneish M Score to see the likelihood of Janux Therapeutics' management manipulating its earnings.
Evaluate Janux Therapeutics' management efficiency
Janux Therapeutics has return on total asset (ROA) of (0.0857) % which means that it has lost $0.0857 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1009) %, meaning that it created substantial loss on money invested by shareholders. Janux Therapeutics' management efficiency ratios could be used to measure how well Janux Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2025. Return On Capital Employed is likely to rise to -0.09 in 2025. At this time, Janux Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 387.3 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 17.2 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 19.03 | 19.98 | |
| Tangible Book Value Per Share | 19.03 | 19.98 | |
| Enterprise Value Over EBITDA | (24.99) | (26.24) | |
| Price Book Value Ratio | 2.81 | 2.95 | |
| Enterprise Value Multiple | (24.99) | (26.24) | |
| Price Fair Value | 2.81 | 2.95 | |
| Enterprise Value | 2.5 B | 2.6 B |
Leadership effectiveness at Janux Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 3.223 |
Basic technical analysis of Janux Stock
As of the 24th of March, Janux Therapeutics retains the Market Risk Adjusted Performance of (0.71), standard deviation of 4.01, and Risk Adjusted Performance of (0.21). Janux Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Janux Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Janux Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Janux Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Janux Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Janux Therapeutics' Outstanding Corporate Bonds
Janux Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Janux Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Janux bonds can be classified according to their maturity, which is the date when Janux Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Janux Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Janux Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.21) | |||
| Market Risk Adjusted Performance | (0.71) | |||
| Mean Deviation | 2.83 | |||
| Coefficient Of Variation | (403.23) | |||
| Standard Deviation | 4.01 | |||
| Variance | 16.12 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (0.70) | |||
| Treynor Ratio | (0.72) | |||
| Maximum Drawdown | 20.17 | |||
| Value At Risk | (7.56) | |||
| Potential Upside | 8.08 | |||
| Skewness | 0.4025 | |||
| Kurtosis | 1.68 |
| Risk Adjusted Performance | (0.21) | |||
| Market Risk Adjusted Performance | (0.71) | |||
| Mean Deviation | 2.83 | |||
| Coefficient Of Variation | (403.23) | |||
| Standard Deviation | 4.01 | |||
| Variance | 16.12 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (0.70) | |||
| Treynor Ratio | (0.72) | |||
| Maximum Drawdown | 20.17 | |||
| Value At Risk | (7.56) | |||
| Potential Upside | 8.08 | |||
| Skewness | 0.4025 | |||
| Kurtosis | 1.68 |
Consider Janux Therapeutics' intraday indicators
Janux Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Janux Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Janux Therapeutics Corporate Filings
| 10th of March 2025 Other Reports | ViewVerify | |
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Janux Stock media impact
Far too much social signal, news, headlines, and media speculation about Janux Therapeutics that are available to investors today. That information is available publicly through Janux media outlets and privately through word of mouth or via Janux internal channels. However, regardless of the origin, that massive amount of Janux data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Janux Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Janux Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Janux Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Janux Therapeutics alpha.
Janux Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Janux Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Janux Therapeutics Historical Investor Sentiment
Investor biases related to Janux Therapeutics' public news can be used to forecast risks associated with an investment in Janux. The trend in average sentiment can be used to explain how an investor holding Janux can time the market purely based on public headlines and social activities around Janux Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Janux Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Janux Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Janux Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Janux Therapeutics.
Janux Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts
Janux Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Janux Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Janux Therapeutics' options.
Janux Therapeutics Corporate Management
| Brenda Vreeswyk | Head Resources | Profile | |
| Zachariah DO | Chief Officer | Profile | |
| Wayne MD | Chief Officer | Profile | |
| Matt Whitmire | Vice Finance | Profile | |
| Charles Winter | Manufacturing Chemistry | Profile | |
| CFA CPA | Acting Officer | Profile | |
| Andy Meyer | Chief Officer | Profile |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.